IGHE and asthma: By impending the binding of this relevant alarmin in the pathogenesis of asthma with its receptor, tezepelumab inhibits multiple downstream inflammatory pathways and reduces biomarkers and cytokines associated with inflammation including blood eosinophils, airway submucosal eosinophils, FeNO, IgE, IL-5 and IL-13 [16].